



**MEDIA CONTACTS:**

Steve Winter, Brotman | Winter | Fried

swinter@aboutbwfcom; 202-468-8100

Heather Mahoney, Brotman | Winter | Fried

hmahoney@aboutbwfcom; 240-271-5762

## **Council for Federal Cannabis Regulation (CFCR) March Webinar to Focus on Effectiveness of Cannabinoid Integration into Commercial Products**

*Next CFCR Event Scheduled for Thursday, March 31, 1:00 - 2:00 p.m. EST*

**WASHINGTON, D.C. (March 8, 2022)** The [Council for Federal Cannabis Regulation](#) (CFCR) announced today the sixth episode of their monthly webinar series entitled **Understanding Real World Evidence on the Effectiveness of Cannabinoid Products**. Scheduled to take place Thursday, March 31, from 1:00 until 2:00 p.m. EST, this program will dive into the results of the recent Radicle ACES (Advancing CBD Education & Science) study and highlight how the real world evidence (RWE) outcomes from the study are helping to better inform consumer perspectives on the effectiveness of cannabinoid-based products.

The program will be moderated by CFCR's Executive Director **Sarah A. Chase** along with Council Advisory Board Member **Jack Jacobson**, a cannabis, energy and education practices advisor for Thompson Coburn LLC. The panel will consist of **Pelin Thorogood** and **Dr. Jeffrey Chen**, the two co-founders of [Radicle Science](#), a transformative health tech company that offers a scalable path toward predicting and validating the effects of health and wellness products for ailments or the enhancement of human function; and **Tim Orr**, Senior VP of R&D and President of [Charlotte's Web Labs](#), a company that produced the now-legendary treatment regimen for six-year-old Charlotte Figi that helped to ultimately affect a seismic shift in public opinion toward the use of medicinal cannabis.

In a uniquely "democratized" approach to academic research, the Radicle ACES study is the first multi-brand, Institutional Review Board (IRB) approved study on CBD effectiveness across well-being, quality of life, pain, sleep disturbance, and anxiety. The results to be discussed on this webinar shall offer insights on the findings of this first-of-its-kind randomized controlled trial (RCT) that collected health outcome data on 13 participating CBD brands across nearly 3,000 participants throughout the U.S. over a period of four weeks.

The event will take place over the ON24 Video Conference Platform, **Thursday, March 31**, from 1:00 until 2:00 p.m. EST.

Through their monthly presentations, CFCR has explored various facets of the cannabis industry – including the regulatory impacts of a groundbreaking CBD study, as well as Federal and state cannabis policies. Last month's focus on the Endocannabinoid System and its implications for research and regulation drew more than 300 attendees, pushing their total participation in these programs well past the thousand person mark.

Ongoing webinars will take place on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today's legal cannabis molecules and products. These virtual sessions can be viewed through the On24 platform. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

Speaker Profiles for the March 31 Webinar:

### **Tim Orr, SVP R&D and President Charlotte's Web Labs**



Tim Orr is a global healthcare leader with over 30 years healthcare industry experience including general management, strategic and product marketing, U.S. and International sales/marketing/services management, global product development, and global product launch execution. Prior to joining Charlotte's Web, Tim spent more than 25 years at Johnson & Johnson Company with the \$2B Laboratory Sciences Group where he held leadership positions spanning all aspects of commercial operations.

Prior to Johnson & Johnson Tim worked for Amersham International, a Life Sciences Company, and Abbott Laboratories. Tim has spent one third of his career living and working in overseas locations including; London England, where was the General Manager responsible for Clinical Labs product development, Tokyo Japan as the Regional Director, and Singapore as General Manager ASPAC region.

Upon return to the US, Tim was responsible for the U.S. Region, Commercial Operations. Tim holds a BA degree in Chemistry and a Master's Degree in Organizational Leadership.

### **Pelin Thorogood, Co-Founder, Executive Chairwoman, Radicle Science**




Tech CEO, Impact Entrepreneur and Trailblazer -- Pelin Thorogood is an analytics industry executive-turned startup founder who has made a career out of being at the forefront of emerging business trends and disruptive technologies.

With an unwavering focus on data and analytics, Pelin served as CEO and Director of Anametrix, a venture-backed multichannel data collection, visualization, and predictive analytics platform which received broad industry recognition, including for best business intelligence (BI) and Big Data solution (acquired by Ensignen 2014). Prior to Anametrix, she was CMO of WebSideStory, the pioneer in web analytics (IPO 2004, acquired by Omniture/Adobe 2008).

Pelin is the Co-Founder and President of Wholistic Research, and Education Foundation, one of the very first non-profits (501c3) focused on funding cutting-edge cannabinoid research and education to improve public health and safety. With a deep commitment to education and community, Pelin also serves as a Trustee and Treasurer of the [UC San Diego Foundation](#) and is on the Executive Board of the [UC San Diego Basement](#), a campus-wide incubator for innovation and entrepreneurship. Pelin earned her B.S., M.Eng. and MBA degrees on merit scholarships, all from Cornell, where she still serves as an Industry Scholar for Cornell Institute of Healthy Futures.

## Dr. Jeff Chen, Co-Founder & CEO, Radicle Science



Scientist, impact entrepreneur and chief storyteller for Radicle Science, Dr. Jeff Chen was the founder and a past Executive Director of the UCLA Cannabis Research Initiative (one of the world's first), which he grew to encompass more than 40 members of the institutional faculty, conducting research, education, and policy projects.

Jeff has experience as Founder, Managing Partner, Investor, Board Member, and Advisor to companies, not-for-profits, and venture firms in life science, sustainability, tech, and media. Featured in such media outlets as *Rolling Stone*, the *Wall Street Journal*, *VICE*, *CNN*, *NPR*, *Entrepreneur*, *Business Insider*, *Politico* and others, Jeff is part of the Medical Team at Healthline Media (86M visitors/month). He's a David Geffen Fellow, U.S. patent holder, Industry Mentor for the U.S. National Institutes of Health Innovation CORPs, and Chief Science Officer of the Wholistic Research and Education Foundation

Jeff earned his MD and MBA concurrently at UCLA on a full merit scholarship, following a B.S. at Cornell.

\* \* \*

To register for this CFCR's webinar series, please visit: <https://www.uscfc.org/events>

For additional information, please visit [uscfc.org](https://www.uscfc.org).

#####

### ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit [www.uscfc.org](https://www.uscfc.org) and follow us on social media @USCFCR.